Literature DB >> 10898510

Efficient protection against Mycobacterium tuberculosis by vaccination with a single subdominant epitope from the ESAT-6 antigen.

A W Olsen1, P R Hansen, A Holm, P Andersen.   

Abstract

We have investigated the vaccine potential of two peptides derived from the 6-kDa early secretory antigenic target (ESAT)-6 antigen in the mouse model of tuberculosis. The peptides were both strongly immunogenic in B6CBAF1 (H-2b,k) mice and primed recall responses of the same intensity after immunization. However, both tuberculosis infection and immunization with ESAT-6 resulted in responses focused towards ESAT-61-20. Multiple antigen peptide constructs as well as free peptides were emulsified with dimethyl dioctadecylammonium bromide/monophosphoryl lipid A/IL-2 and tested as experimental vaccines in an i.v. and aerosol model of tuberculosis in mice. The peptide were highly immunogenic and induced cellular responses of the same magnitude. However, only vaccines based on the subdominant ESAT-651-70 epitope promoted significant levels of protective immunity and the level of protection was equivalent to that achieved with ESAT-6 and BCG. These findings demonstrate the potential of peptide-based vaccines against tuberculosis and indicate that there is not direct correlation between the hierarchy of response to naturally processed peptides and their ability to induce protective immunity against Mycobacterium tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10898510     DOI: 10.1002/1521-4141(200006)30:6<1724::AID-IMMU1724>3.0.CO;2-A

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  41 in total

1.  Vaccination with a single CD4 T cell peptide epitope from a Salmonella type III-secreted effector protein provides protection against lethal infection.

Authors:  Jonathan R Kurtz; Hailey E Petersen; Daniel R Frederick; Lisa A Morici; James B McLachlan
Journal:  Infect Immun       Date:  2014-03-31       Impact factor: 3.441

Review 2.  Antigens for CD4 and CD8 T cells in tuberculosis.

Authors:  Cecilia S Lindestam Arlehamn; David Lewinsohn; Alessandro Sette; Deborah Lewinsohn
Journal:  Cold Spring Harb Perspect Med       Date:  2014-05-22       Impact factor: 6.915

3.  Recombinant adenovirus delivery of calreticulin-ESAT-6 produces an antigen-specific immune response but no protection against a Mycobacterium tuberculosis challenge.

Authors:  S C Esparza-González; A Troy; J Troudt; M J Loera-Arias; J Villatoro-Hernández; E Torres-López; J Ancer-Rodríguez; Y Gutiérrez-Puente; G Muñoz-Maldonado; O Saucedo-Cárdenas; R Montes-de-Oca-Luna; A Izzo
Journal:  Scand J Immunol       Date:  2012-03       Impact factor: 3.487

4.  Broadening CD4+ and CD8+ T Cell Responses against Hepatitis C Virus by Vaccination with NS3 Overlapping Peptide Panels in Cross-Priming Liposomes.

Authors:  Jonathan Filskov; Marianne Mikkelsen; Paul R Hansen; Jan P Christensen; Allan R Thomsen; Peter Andersen; Jens Bukh; Else Marie Agger
Journal:  J Virol       Date:  2017-06-26       Impact factor: 5.103

5.  Antitumor efficacy of viable tumor vaccine modified by heterogenetic ESAT-6 antigen and cytokine IL-21 in melanomatous mouse.

Authors:  Xiangfeng He; Jing Wang; Fengshu Zhao; Fangliu Yu; Dengyu Chen; Kai Cai; Cuiping Yang; Junsong Chen; Jun Dou
Journal:  Immunol Res       Date:  2012-06       Impact factor: 2.829

6.  High mobility group box 1 acts as an adjuvant for tuberculosis subunit vaccines.

Authors:  Ajay Grover; Jolynn Troudt; Chad Foster; Randall Basaraba; Angelo Izzo
Journal:  Immunology       Date:  2014-05       Impact factor: 7.397

7.  Mycobacterium tuberculosis directs immunofocusing of CD8+ T cell responses despite vaccination.

Authors:  Joshua S Woodworth; Daniel Shin; Mattijs Volman; Cláudio Nunes-Alves; Sarah M Fortune; Samuel M Behar
Journal:  J Immunol       Date:  2010-12-22       Impact factor: 5.422

8.  The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis.

Authors:  Claire Swetman Andersen; Jes Dietrich; Else Marie Agger; Nils Y Lycke; Karin Lövgren; Peter Andersen
Journal:  Infect Immun       Date:  2006-10-30       Impact factor: 3.441

9.  Characterisation of a live Salmonella vaccine stably expressing the Mycobacterium tuberculosis Ag85B-ESAT6 fusion protein.

Authors:  Lindsay J Hall; Simon Clare; Derek Pickard; Simon O Clark; Dominic L F Kelly; Moataz Abd El Ghany; Christine Hale; Jes Dietrich; Peter Andersen; Philip D Marsh; Gordon Dougan
Journal:  Vaccine       Date:  2009-09-13       Impact factor: 3.641

10.  Mycobacterium tuberculosis Rv0679c protein sequences involved in host-cell infection: potential TB vaccine candidate antigen.

Authors:  Diana P Cifuentes; Marisol Ocampo; Hernando Curtidor; Magnolia Vanegas; Martha Forero; Manuel E Patarroyo; Manuel A Patarroyo
Journal:  BMC Microbiol       Date:  2010-04-13       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.